Jason Carroll
Molecular oncologist and Interim Director of the Cancer Research UK Cambridge Institute, known for mapping how the oestrogen receptor drives breast cancer.
Overview
Jason Carroll is Interim Director of the Cancer Research UK Cambridge Institute, where he is a Senior Group Leader, and Professor of Molecular Oncology at the University of Cambridge. His laboratory studies oestrogen receptor and FOXA1 transcriptional networks in breast cancer, including the landmark demonstration that differential ER binding patterns predict clinical outcome. His work underpins efforts to overcome endocrine therapy resistance.
| Title | Journal | Year |
|---|---|---|
| Differential oestrogen receptor binding is associated with clinical outcome in breast cancer | Nature | 2012 |
Pages like this
not linked directly; found by shared links- PersonJames Brenton
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute and the tags leadership, clinician-scientist.
- PersonDorraya El-Ashry
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
- PersonEva Ciruelos
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
- PersonMafalda Oliveira
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
- PersonCharlotte E. Coles
Shares Cancer Research UK Cambridge Centre / CRUK Cambridge Institute, HR-positive / HER2-negative breast cancer.
- PersonAnna Sapino
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
- PersonTari A. King
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.
- PersonMarek Svoboda
Shares HR-positive / HER2-negative breast cancer and the tags leadership, clinician-scientist, breast cancer.